Genentech Expands Deal with Molecular Glue Biotech Orionis for $105M Upfront
Summary by Endpoints News
3 Articles
3 Articles
All
Left
Center
Right
Genentech expands deal with molecular glue biotech Orionis for $105M upfront
Roche’s subsidiary Genentech is signing a second deal with Orionis Biosciences to expand its search through the world of protein interactions in hopes of developing new cancer drugs. The two companies first partnered in 2023 ...
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage